HomeMedicare Dispatch → Examining CMS' proposed cancer drugs pilot

Examining CMS' proposed cancer drugs pilot Print E-mail
Written by Carolyn Johnson | The Washington Post   
Tuesday, 12 April 2016 00:00

A controversial effort by the Obama administration to reform how doctors earn money from administering injection drugs would reduce their earnings on the most expensive drugs while making many older generics more lucrative, according to a new analysis.

A high-stakes debate exploded last month over the administration's drug payment pilot program, which would test a fundamental change in how doctors are reimbursed for giving chemotherapy and other injectable drugs through Medicare. Medicare has said the pilot would remove a perverse incentive for doctors to prescribe the most expensive drugs, while the drug industry, doctors and disease groups argue it would threaten small cancer practices and seniors' health.

The opposition to the pilot shared by drug companies and doctors -- parties that don't always see eye-to-eye on drug prices -- led Peter Bach, director of the Center for Health Policy Outcomes at Memorial Sloan Kettering Cancer Center to look more closely at how the policy would affect reimbursements...

Read More>>

Last Updated on Wednesday, 13 April 2016 14:37

Website design, development, and hosting provided by